Entecavir + tenofovir works well for people with hepatitis B who have had prior treatment failure
Faldaprevir effective across patient sub-groups with several baseline characteristics associated with treatment outcomes
Faldaprevir safe and effective in HCV treatment-experienced patients
Successful hepatitis C treatment reduces risk of liver cancer and death, but most remain untreated
Sofosbuvir/ribavirin for 24 weeks cures most genotype 3 hepatitis C patients, adding interferon may help difficult-to-treat
Faldaprevir plus pegylated interferon/ribavirin leads to early sustained response in people with HIV and HCV co-infection
Daclatasvir + asunaprevir cures 85% of genotype 1b hepatitis C patients in Japanese study
Fixed-dose sofosbuvir/ledipasvir with or without ribavirin cures most genotype 1 hepatitis C patients, LONESTAR study shows
Sofosbuvir taken before or after liver transplant reduces hepatitis C recurrence
Hepatitis B treatment with entecavir or tenofovir lowers, but does not eliminate, liver cancer risk
Sofosbuvir + ribavirin produces sustained response in 76% of genotype 1 HIV/HCV co-infected people
Simeprevir + sofosbuvir produces high sustained response rates for hard-to-treat patients in COSMOS trial
BMS interferon-free combination cures over 90% of genotype 1 hepatitis C in 12 weeks
Merck interferon-free combination shows high hepatitis C cure rate in early study
Need for expansion of hepatitis C screening among veterans, 'baby-boom' generation and pregnant women highlighted
AbbVie’s two-drug, interferon-free combination cures genotype 1b hepatitis C infection in 95%
High response rates with telaprevir triple therapy for HIV-positive men with acute hepatitis C
In ELECTRON trial, 100% of hard-to-treat patients cured with sofosbuvir/ledipasvir plus ribavirin or GS-9669
